Back to News
Activism

Activist Investing Today: Skadden's Breheny on Expected SEC Shifts

|
Published: June 13th, 2025
Brian Breheny, the former chief of the SEC's M&A division, discusses expected changes to regulations affecting activist investors, including why he thinks the nation's securities regulator can eliminate activist shareholder proposals.

The Securities and Exchange Commission has the authority to eliminate abolish shareholder proposals, though insurgent investors would likely challenge such a move, explained Brian Breheny, partner and co-head of the SEC reporting and compliance practice at Skadden, Arps, Slate, Meagher & Flom LLP.

“Could they eliminate 14a-8 shareholder proposals? I think the answer is yes,” Breheny said on the Activist Investing Today podcast. “There isn’t anything preventing the SEC from changing its mind and saying, ‘We thought that having these rules at certain percentages was right and now it’s no longer right.'”

In a conversation about the securities regulator’s expected shift under recently installed SEC Chairman Paul Atkins, Breheny said the agency would likely get hit with a legal challenge if it sought to end shareholder proposals.

Before joining Skadden, Breheny held several leadership positions in the SEC’s Division of Corporation Finance, including as chief of the Office of Mergers and Acquisitions, as well as deputy director, legal and regulatory policy in the division.

On the podcast, Breheny talked about his expectations for short-sale disclosure rules that the agency recently postponed; and why he thinks a long-languishing proposal on derivatives reporting likely will never be adopted.

He also discussed controversial new guidance affecting how index funds communicate with corporations and why recently approved Texas legislation requiring shareholders to own $1 million or 3% of a company’s voting securities to submit shareholder proposals at companies headquartered or incorporated in the Lone Star State doesn’t conflict with SEC rules.

Check out the podcast with Brian Breheny:

More podcasts from The Deal are available on iTunesSpotify and on TheDeal.com.

More From Activism

Activism

Activist Investing Today: Eldar on Anti-Activist Pill Evolution

By Ronald Orol
|
Published: May 23rd, 2025
When corporations install anti-activist poison pills they're less likely to implement new share buybacks and their operationally focused capital expenditures tend to be higher, UC Berkeley School of Law professor Ofer Eldar explains.
Activism

Pills Emerge Amid Tariff Uncertainty, Activism

By Ronald Orol
|
Published: April 28th, 2025
As the markets face tariff-related volatility, some companies, especially biotechnology and pharmaceuticals companies, are setting up or extending shareholder rights plans, known as poison pills, to discourage unsolicited bidders and activist accumulations.